Manuel Mateo Pérez Encinas-rekin lankidetzan egindako argitalpenak (16)

2024

  1. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  2. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  3. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  2. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

2022

  1. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  2. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

    British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538

  3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

2021

  1. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 371-379

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

2018

  1. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  2. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

    Leukemia

  3. Prognostic risk models for transplant decision-making in myelofibrosis

    Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820

2017

  1. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis

    European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414

  2. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109

2016

  1. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

    Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732